InnoCare’s Zurletrectinib Wins NMPA Nod as China’s First Next-Gen TRK Inhibitor
InnoCare Pharma Limited (SHA: 688428, HKG: 9969) announced that its self‑developed next‑generation TRK inhibitor, Zurletrectinib...
Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery
Brii Biosciences Limited (HKG: 2137) announced a collaboration with OpenBench to leverage its structure‑driven Artificial...
GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs
UK biopharma GlaxoSmithKline plc (GSK, NYSE: GSK) has initiated a breakup with Ideaya Biosciences (NASDAQ:...
B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline
B&K Corporation Limited (HKG: 2396) officially listed on the Hong Kong Stock Exchange today, offering...
OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform
Oxford BioTherapeutics (OBT), a clinical‑stage oncology company, announced a multi‑year, multi‑target strategic collaboration with GSK...
Lilly to Invest Over $6 Billion in Alabama GLP‑1 Manufacturing Hub for Orforglipron
Eli Lilly & Co. (NYSE: LLY) announced plans to invest more than USD 6 billion in a...
Sino Biopharm’s Culmerciclib Wins NMPA Approval as First CDK2/4/6 Inhibitor for Breast Cancer
Sino Biopharmaceutical (HKG: 1177) announced that Culmerciclib Capsules, the world’s first CDK2/4/6 inhibitor, received marketing...
Insilico Licenses AI‑Designed ISM4808 PHD Inhibitor to TaiGen in Two‑Digit Million Dollar Greater China Deal
Insilico Medicine and TaiGen Biotechnology (including its Beijing subsidiary TaiGen Biopharmaceuticals) announced an exclusive pipeline...
Lobemilast (Y‑3) NDA Accepted by NMPA as First Multi‑Target Stroke Neuroprotectant
Neurodawn Pharmaceutical Co., Ltd. announced that its self‑developed Category 1 chemical drug, Y‑3 for Injection (generic...
Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal
Lynk Pharmaceuticals Co., Ltd. and Formation Bio announced that Bleecker Bio, a newly formed Formation...
Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension
Shanghai Pharmaceuticals Holding Co., Ltd. (SHA: 601607) announced that the National Medical Products Administration (NMPA)...
Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors
Shanghai Juncell Therapeutics Co., Ltd. (“JunCell Biologics”) released its prospectus, announcing its intention to list...
Relation Therapeutics and Novartis Forge $1.7 Billion Alliance for AI‑Driven Atopic Disease Targets
Relation Therapeutics Limited announced a multi‑program strategic collaboration with Novartis AG (NYSE: NVS) to discover...
Sanofi’s Qfitlia Wins China Approval as First Hemophilia siRNA Therapy
Sanofi (NASDAQ: SNY) announced that Qfitlia (Fitusiran Sodium Injection), the world’s first and only siRNA‑based...
Zealand Pharma and OTR Therapeutics Seal $2.5 Billion Metabolic Disease Partnership
OTR Therapeutics announced a strategic collaboration and licensing agreement with Zealand Pharma A/S (NASDAQ: ZEAL)...
Innovent’s PECONDLE Meets Phase 3 IL‑23 Psoriasis Endpoints with Quarterly Dosing
Innovent Biologics, Inc. (HKG: 1801) announced that PECONDLE (picankibart injection, IBI112), its self‑developed anti‑IL‑23p19 monoclonal...
D3 Bio Closes $108 M Series B to Advance Elisrasib KRAS G12C Phase 3 Trials Globally
D3 Bio, a globally focused biotechnology company, announced the completion of a USD 108 million Series B...
Fosun Pharma Licenses Oral GLP‑1R Agonist YP05002 to Pfizer in $2.1 Billion Deal
Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced that its subsidiary Chongqing Yaopharma...
Qilu Pharmaceutical Secures China Approval for Panitumumab N01, First Fully Human anti‑EGFR Antibody in Colorectal Cancer
Qilu Pharmaceutical Company Limited announced that its Panitumumab N01 Injection has received marketing approval from...
Innovent Doses First Patient in Phase 1 Trial of IBI3011, China’s First Anti‑IL‑1RAP Antibody for Gout Flares
Innovent Biologics, Inc. (HKG: 1801) announced that the first participant has been dosed in a...